Microbiota-Derived Extracellular Vesicles as a Postbiotic Strategy to Alleviate Diarrhea and Enhance Immunity in Rotavirus-Infected Neonatal Rats.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Rotavirus* ; Extracellular Vesicles* ; Rotavirus Infections*/therapy ; Microbiota* ; Vaccines*; Child ; Humans ; Animals ; Rats ; Child, Preschool ; Animals, Newborn ; Escherichia coli ; Diarrhea/therapy

Rotavirus (RV) infection is a major cause of acute gastroenteritis in children under 5 years old, resulting in elevated mortality rates in low-income countries. The efficacy of anti-RV vaccines is limited in underdeveloped countries, emphasizing the need for novel strategies to boost immunity and alleviate RV-induced diarrhea. This study explores the effectiveness of interventions involving extracellular vesicles (EVs) from probiotic and commensal E. coli in mitigating diarrhea and enhancing immunity in a preclinical model of RV infection in suckling rats. On days 8 and 16 of life, variables related to humoral and cellular immunity and intestinal function/architecture were assessed. Both interventions enhanced humoral (serum immunoglobulins) and cellular (splenic natural killer (NK), cytotoxic T (Tc) and positive T-cell receptor γδ (TCRγδ) cells) immunity against viral infections and downregulated the intestinal serotonin receptor-3 (HTR3). However, certain effects were strain-specific. EcoR12 EVs activated intestinal CD68 , TLR2 and IL-12 expression, whereas EcN EVs improved intestinal maturation, barrier properties (goblet cell numbers/mucin 2 expression) and absorptive function (villus length). In conclusion, interventions involving probiotic/microbiota EVs may serve as a safe postbiotic strategy to improve clinical symptoms and immune responses during RV infection in the neonatal period. Furthermore, they could be used as adjuvants to enhance the immunogenicity and efficacy of anti-RV vaccines.

Virology. 2005 Jul 5;337(2):210-21. (PMID: 15882887)
Front Immunol. 2020 Jan 23;11:15. (PMID: 32038659)
FEBS J. 2021 Dec;288(24):7060-7072. (PMID: 33507606)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
FEMS Microbiol Lett. 2016 Oct;363(19):. (PMID: 27619890)
Lancet Infect Dis. 2012 Feb;12(2):136-41. (PMID: 22030330)
J Virol. 2003 Dec;77(24):13005-16. (PMID: 14645557)
Front Immunol. 2016 Dec 05;7:563. (PMID: 27994593)
Microbes Infect. 2001 Nov;3(13):1145-56. (PMID: 11709295)
Medicina (B Aires). 2003;63(4):293-8. (PMID: 14518142)
Neurogastroenterol Motil. 2015 Sep;27(9):1239-48. (PMID: 26088715)
Hum Vaccin Immunother. 2019;15(6):1237-1250. (PMID: 30215578)
Sci Rep. 2015 Nov 30;5:17324. (PMID: 26616662)
Int J Mol Sci. 2023 Apr 16;24(8):. (PMID: 37108513)
Trends Immunol. 2014 Nov;35(11):526-37. (PMID: 25113637)
Caspian J Intern Med. 2015 Fall;6(4):187-95. (PMID: 26644891)
J Nutr. 1993 Nov;123(11):1939-51. (PMID: 8229312)
Clin Infect Dis. 2022 Aug 24;75(1):41-46. (PMID: 34788820)
Annu Rev Immunol. 2021 Apr 26;39:51-76. (PMID: 33428453)
mSphere. 2022 Oct 26;7(5):e0027022. (PMID: 36073800)
BMC Microbiol. 2019 Jul 17;19(1):166. (PMID: 31315566)
Pediatr Res. 2007 Dec;62(6):658-63. (PMID: 17957154)
Cells. 2019 Aug 11;8(8):. (PMID: 31405262)
Nutrients. 2020 Jul 23;12(8):. (PMID: 32717965)
J Infect Dis. 2007 Aug 15;196(4):537-40. (PMID: 17624838)
Nat Rev Dis Primers. 2017 Nov 09;3:17083. (PMID: 29119972)
Annu Rev Microbiol. 2021 Oct 8;75:609-630. (PMID: 34351789)
Res Vet Sci. 2017 Feb;110:12-15. (PMID: 28159230)
Int J Mol Sci. 2017 Jun 16;18(6):. (PMID: 28621731)
PLoS One. 2021 Feb 16;16(2):e0246193. (PMID: 33592026)
Front Cell Infect Microbiol. 2021 Jan 08;10:586751. (PMID: 33489932)
Int J Mol Sci. 2021 Aug 31;22(17):. (PMID: 34502396)
PLoS Pathog. 2011 Jul;7(7):e1002115. (PMID: 21779163)
J Immunol. 2016 Feb 15;196(4):1780-9. (PMID: 26800875)
J Bacteriol. 1984 Feb;157(2):690-3. (PMID: 6363394)
Nutrients. 2020 Feb 15;12(2):. (PMID: 32075234)
PLoS One. 2012;7(8):e41720. (PMID: 22879893)
J Control Release. 2020 Jul 10;323:253-268. (PMID: 32333919)
Probiotics Antimicrob Proteins. 2023 Feb;15(1):107-128. (PMID: 35034323)
World J Gastroenterol. 2016 Jun 28;22(24):5505-11. (PMID: 27350728)
Vaccine. 2013 Jan 7;31(3):452-60. (PMID: 23153448)
Nutrients. 2020 Jan 31;12(2):. (PMID: 32024037)
Eur J Immunol. 2016 Oct;46(10):2426-2437. (PMID: 27457183)
J Infect Dis. 2011 Jan 15;203(2):188-95. (PMID: 21288818)
PLoS One. 2016 Jul 26;11(7):e0159660. (PMID: 27459372)
Nutrients. 2022 Dec 13;14(24):. (PMID: 36558455)
Science. 2000 Jan 21;287(5452):491-5. (PMID: 10642552)
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):649-667. (PMID: 33948025)
J Extracell Vesicles. 2021 Nov;10(13):e12161. (PMID: 34738337)
PLoS One. 2016 Oct 11;11(10):e0164512. (PMID: 27727323)
PLoS Pathog. 2021 May 13;17(5):e1009508. (PMID: 33984071)
BMC Infect Dis. 2010 Aug 25;10:253. (PMID: 20735858)
Vaccine. 2006 Apr 5;24(15):2718-31. (PMID: 16446014)
Nutrients. 2022 Mar 10;14(6):. (PMID: 35334820)
Nutrients. 2020 Jun 24;12(6):. (PMID: 32599899)
Nat Rev Microbiol. 2023 Jul;21(7):415-430. (PMID: 36932221)
J Mol Biol. 2014 Mar 20;426(6):1246-64. (PMID: 24316048)
Front Immunol. 2017 Mar 27;8:334. (PMID: 28396664)
Eur J Pediatr. 2007 Apr;166(4):311-8. (PMID: 17287932)
Front Immunol. 2015 Dec 07;6:613. (PMID: 26697009)
Nutrients. 2023 Nov 06;15(21):. (PMID: 37960354)
Cell. 2015 Apr 9;161(2):264-76. (PMID: 25860609)
PLoS One. 2016 Oct 13;11(10):e0164775. (PMID: 27736989)
Nutrients. 2023 May 24;15(11):. (PMID: 37299399)
Sci Rep. 2021 Nov 19;11(1):22624. (PMID: 34799637)
Transl Pediatr. 2021 Dec;10(12):3248-3260. (PMID: 35070839)
Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):237-44. (PMID: 25459995)
Vaccines (Basel). 2022 Jan 06;10(1):. (PMID: 35062744)
J Virol. 2021 Jul 12;95(15):e0075121. (PMID: 33980599)
Gut Pathog. 2016 Dec 13;8:66. (PMID: 27999620)
J Diabetes Metab Disord. 2020 May 1;19(1):597-604. (PMID: 32550212)
Mucosal Immunol. 2012 Nov;5(6):712-9. (PMID: 22739233)
Emerg Infect Dis. 2006 Feb;12(2):304-6. (PMID: 16494759)
Nutrients. 2022 Jan 14;14(2):. (PMID: 35057528)
Sci Rep. 2020 Dec 17;10(1):22119. (PMID: 33335202)
Microorganisms. 2023 May 09;11(5):. (PMID: 37317221)
Eur J Nutr. 2017 Jun;56(4):1657-1670. (PMID: 27112962)
Int J Mol Sci. 2019 Sep 20;20(19):. (PMID: 31547172)
Probiotics Antimicrob Proteins. 2021 Dec;13(6):1546-1556. (PMID: 33852147)
Front Cell Infect Microbiol. 2018 Oct 23;8:372. (PMID: 30406046)
Nat Rev Immunol. 2015 Jun;15(6):375-87. (PMID: 25976515)

PID2019-107327RB-100 Ministerio de Ciencia e Innovación

Keywords: extracellular vesicles; immunomodulation; intestinal serotonin; microbiota–host communication; postbiotics; probiotics; rotavirus

0 (Vaccines)

Date Created: 20240123 Date Completed: 20240124 Latest Revision: 20240128

20240128

PMC10816611

10.3390/ijms25021184

38256253